Latest Breaking News On - Itch severity - Page 1 : comparemela.com

Rilzabrutinib, an oral BTK inhibitor, demonstrates efficacy in reducing itch and disease activity among patients with chronic spontaneous urticaria in phase 2 dose-ranging trial at AAAAI 2024.

United statesMarcus maurerAmerican academy of allergyInstitute of allergologyCharite berlinAnnual meetingItch severityChronic spontaneous urticariaAaaai 2024 late breakerCsu treatmentsChronic spontaneous urticaria csuOral btk inhibitorsBtk inhibitor